BACK TO BASELINE WEBINAR #2

New Tech, Real Impacts - How Multi-path Neurostimulation Can Enhance Addiction Recovery Outcomes

NOVEMBER 30 | 1p EST | Digital

ADJUNCT THERAPY STUDY RESULTS

Adding new treatments to current OUD protocols shown to drive better patient recovery retention.

A new study conducted in partnership Hazelden Betty Ford shows the exciting impacts that adding Spark Multi-path Neurostimulation treatments to existing protocols can generate - including an almost 7X elevation in patient program retention. 

Join Navid Khodaparast from Spark Biomedical as he welcomes Dr. Carlos Tirado along with Dr. Alta DeRoo and Dr. Quyen Ngo from Hazelden Betty Ford to review the results of the RESTORE in-practice treatment study on November 30th in an interactive webinar.

This is no data dump – it’s a clear and powerful story built to help inform addiction recovery pros, whether you’re in a clinical role, a care-planning role, or a policy decision role.

Join our experts for an exciting discussion on November 30th – reserve your spot today.
6.9 graphic hex

Reserve your spot for NOV 30TH at 1pm EST

Hear study highlights from the addiction experts behind it. 

Navid, Chief Science Officer and co-founder of Spark

Dr. Navid Khodaparast

Chief Science Officer and Co-founder of Spark Biomedical

DeRoo_17USE-opt

Dr. Alta DeRoo

Chief Medical Officer, Hazelden Betty Ford Foundation

Carlos F. Tirado, Head of Cytogenetics at Stony Brook Medicine

Dr. Carlos F. Tirado

Senior Medical Advisor, Spark Biomedical

Dr. Quyen Ngo

Dr. Quyen Ngo, PhD

Executive Director of the Butler Center for Research, Hazelden Betty Ford Foundation